Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus

Posted by:

City of Hope, a world-renowned independent research and cancer treatment center, and Helocyte, Inc., a majority-owned subsidiary of Fortress Biotech, Inc. (NASDAQ:FBIO), announced today that data from the Phase 1 trial of Helocyte’s Triplex vaccine were published online this month in Blood, the journal of the American Society of Hematology.

The vaccine is initially being developed for control of cytomegalovirus (CMV) in allogeneic hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients. In the Phase 1 study, Triplex was found to be safe, well-tolerated and highly immunogenic when administered to healthy volunteers at multiple dose levels. These data supported the initiation of an ongoing Phase 2 trial evaluating Triplex in patients undergoing allogeneic HSCT.

In the Phase 1 trial, City of Hope researchers studied the response to the vaccine in 24 healthy volunteers. They found that Triplex generated robust and durable virus-specific immunity in those previously infected with CMV (addressing patients at greatest risk of viral complications following allogeneic HSCT) as well as in those with no prior CMV infection (addressing patients at greatest risk of viral complications following SOT).

Read the full article at:  http://www.directorstalkinterviews.com/data-from-phase-1-trial-of-triplex-vaccine-for-control-of-cytomegalovirus-published-in-blood/412714251

Image taken from:  http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-5695

0

About the Author:

  Related Posts

Add a Comment